Vistagen Therapeutics (VTGN) Price to Earnings (2012 - 2026)

Vistagen Therapeutics has disclosed Price to Earnings across 15 years of filings, most recently posting 0.78 for Q2 2026.

• In Q2 2026, Price to Earnings rose 80.73% year-over-year to 0.78; the TTM figure through Jun 2026 stood at 0.15 (up 86.28% YoY), while the FY2026 annual figure was 0.34, up 76.33% from the prior year.
• Price to Earnings came in at 0.78 for Q2 2026 at Vistagen Therapeutics, up from 1.44 in the prior quarter.
• In the past five years, Price to Earnings ranged from a high of 0.78 in Q2 2026 to a low of 21.88 in Q4 2023.
• Average Price to Earnings over 5 years is 6.38, with a median of 5.69 recorded in 2024.
• Year-over-year, Price to Earnings surged 95.58% in 2022 and sank 931.27% in 2023.
• Over 5 years, Price to Earnings stood at 2.12 in 2022, then slumped by 931.27% to 21.88 in 2023, then soared by 72.37% to 6.04 in 2024, then jumped by 77.1% to 1.38 in 2025, then jumped by 43.39% to 0.78 in 2026.
• Per Business Quant data, the three most recent Price to Earnings figures were 0.78 in Q2 2026, 1.44 in Q1 2026, and 1.38 in Q4 2025.